Business
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025. The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to responsible pain management. “We are pleased to present this new research to the pain care community,” said Thomas Smith, M.D., Chief Medical Officer, “We believe these findings will provide healthcare professionals with real-world insights that can support clinical decision-making. We believe that ongoing research and data transparency are essential to advancing pain care in a meaningful way.” The poster session will be Thursday, September 4 from 4 – 5:30 p.m. PT. BELBUCA®Poster Number: 10 Treatment Characteristics and Safety of Belbuca®, Buprenorphine Patch, and Oral Schedule II Opioid Treatments among Chronic Low Back Pain Patients without Positive History of Opioid-Use Disorder: A Retrospective US Commercial Claims Analysis Vladimir Zah, et al.Poster Number: 11 Economic Burden of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca® or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis Filip Stanicic, et al.Poster Number: 15 Treatment Characteristics of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca® or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis Vladimir Zah, et al.Poster Number: 16 A Retrospective US Commercial Claims Analysis Comparing the Safety Profile of Belbuca® and Oral Schedule II Long-Acting Opioids Used for Chronic Low-Back Pain Treatment among Patients Previously Treated with Short-Acting Opioids Filip Stanicic, et al.Poster Number: 17 Opioid Use Disorder Outcomes of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca® or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis Dimitrije Grbic, et al..Poster Number: 19 Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids Jody L. Green, et al.Po...